Ambar Qavi
Imperial College London(GB)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, COVID-19 Clinical Research Studies, HIV Research and Treatment, SARS-CoV-2 and COVID-19 Research
Most-Cited Works
- → Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV(2019)698 cited
- → Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial(2020)254 cited
- → Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial(2020)130 cited
- → Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection(2021)72 cited
- → Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes(2021)71 cited
- → Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG(2022)54 cited
- → Patient Portal Functionalities and Patient Outcomes Among Patients With Diabetes: Systematic Review(2020)41 cited
- → Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection(2021)33 cited
- → Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial(2021)32 cited
- → Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens(2024)31 cited